Widmaier E P, Rosen K, Abbott B
Department of Biology, Boston University, Massachusetts 02215.
Endocrinology. 1992 Nov;131(5):2313-8. doi: 10.1210/endo.131.5.1330498.
Intravenous administration of Intralipid 10% increases blood levels of essential free fatty acids. In rats and man, this is associated with an inhibition of GH secretion from the anterior pituitary. Because GH is lipolytic, the inhibition of its secretion may represent a negative feedback action of the fats on pituitary sensitivity to GH-releasing hormone. Since corticosterone, the final secretory product of the rat hypothalamic-pituitary-adrenocortical (HPA) axis, is also lipolytic, we tested the hypothesis that FFA would inhibit the HPA axis. Rats were cannulated via the jugular vein and infused with different doses of heparin-Intralipid 10% or heparin-saline; sequential blood samples were obtained and analyzed for ACTH, corticosterone, FFA, and glucose. Intralipid at 2.85 ml/kg increased plasma FFA to over 3 meq/liter by 15 min, with a return to baseline by 60-90 min. There was no effect of the infusion on plasma osmolarity or pH. At 60 min, plasma ACTH levels were significantly elevated to over 1500 pg/ml in Intralipid-infused rats, but were unchanged in saline controls. This dose of Intralipid increased corticosterone levels by nearly 20-fold at 120 min. At 180 min, corticosterone levels were still significantly greater than those in saline controls. Lower doses of Intralipid also significantly elevated both FFA and corticosterone levels, but by 180 min, levels of both were similar to those in controls. The effects of Intralipid on corticosterone secretion could not be attributed to the presence of glycerol in the suspension, since glycerol infusions had no significant effect on steroid levels compared to those in saline controls. In dexamethasone-pretreated rats, there was no significant rise in plasma corticosterone after either of two Intralipid doses, suggesting that the action of Intralipid was at a site within the HPA axis above the adrenal gland. This finding also suggested that the high steroid levels after Intralipid treatment were not due to interference with the corticosterone RIA. This was verified by the finding that there was no increase in plasma immunoreactive corticosterone after Intralipid infusion into adrenalectomized rats. Intralipid also caused an increase in plasma glucose levels that was first significant at 60 min and declined to baseline by 180 min, possibly reflecting increased autonomic activity or peripheral insensitivity to insulin. The results suggest that high circulating FFA levels activate, rather than inhibit, the HPA axis in rats. Since stress activates glucocorticoid production and increases FFA levels due to lipolysis, it is possible that FFA and the HPA axis constitute a previously unrecognized positive feedback loop.(ABSTRACT TRUNCATED AT 400 WORDS)
静脉注射10%的英脱利匹特可提高必需游离脂肪酸的血液水平。在大鼠和人类中,这与垂体前叶生长激素(GH)分泌受到抑制有关。由于GH具有脂解作用,其分泌受到抑制可能代表脂肪对垂体对生长激素释放激素敏感性的负反馈作用。因为皮质酮是大鼠下丘脑-垂体-肾上腺皮质(HPA)轴的最终分泌产物,也具有脂解作用,所以我们检验了游离脂肪酸(FFA)会抑制HPA轴这一假设。通过颈静脉给大鼠插管,并输注不同剂量的肝素-10%英脱利匹特或肝素-生理盐水;采集连续血样并分析促肾上腺皮质激素(ACTH)、皮质酮、FFA和葡萄糖。2.85毫升/千克的英脱利匹特在15分钟内使血浆FFA升高至超过3毫当量/升,并在60 - 90分钟恢复至基线水平。输注对血浆渗透压或pH值没有影响。在60分钟时,输注英脱利匹特的大鼠血浆ACTH水平显著升高至超过1500皮克/毫升,而生理盐水对照组则无变化。该剂量的英脱利匹特在120分钟时使皮质酮水平升高近20倍。在180分钟时,皮质酮水平仍显著高于生理盐水对照组。较低剂量的英脱利匹特也显著升高了FFA和皮质酮水平,但到180分钟时,两者水平与对照组相似。英脱利匹特对皮质酮分泌的影响不能归因于悬浮液中甘油的存在,因为与生理盐水对照组相比,输注甘油对类固醇水平没有显著影响。在用地塞米松预处理的大鼠中,两种英脱利匹特剂量中的任何一种给药后,血浆皮质酮均无显著升高,这表明英脱利匹特的作用部位在肾上腺上方的HPA轴内。这一发现还表明,英脱利匹特治疗后类固醇水平升高并非由于干扰皮质酮放射免疫分析(RIA)。给肾上腺切除的大鼠输注英脱利匹特后血浆免疫反应性皮质酮没有增加,这一发现证实了这一点。英脱利匹特还导致血浆葡萄糖水平升高,在60分钟时首次显著升高,并在180分钟时降至基线水平,这可能反映了自主神经活动增加或外周对胰岛素不敏感。结果表明,高循环FFA水平激活而非抑制大鼠的HPA轴。由于应激会激活糖皮质激素的产生,并因脂解作用增加FFA水平,所以FFA和HPA轴可能构成了一个此前未被认识的正反馈回路。(摘要截短于400字)